CA2145382A1 - Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement - Google Patents

Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement

Info

Publication number: CA2145382A1
Authority: CA; Canada
Prior art keywords: cells; neu; cell; product; cancer
Prior art date: 1991-08-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002145382A

Other languages

English (en)

Inventor

Sarah S. Bacus

Yosef Yarden

Michael Sela

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yeda Research and Development Co Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-22

Filing date

1992-08-21

Publication date

1993-03-04

1991-08-22 Priority claimed from IL99284A external-priority patent/IL99284A0/xx

1992-08-21 Application filed by Individual filed Critical Individual

1992-08-21 Priority claimed from CA002096417A external-priority patent/CA2096417C/fr

1993-03-04 Publication of CA2145382A1 publication Critical patent/CA2145382A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 71
239000000203 mixture Substances 0.000 title claims description 7
238000011275 oncology therapy Methods 0.000 title description 5
230000004044 response Effects 0.000 title description 3
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 153
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 148
206010028980 Neoplasm Diseases 0.000 claims abstract description 48
201000011510 cancer Diseases 0.000 claims abstract description 31
108700020796 Oncogene Proteins 0.000 claims abstract description 28
102000043276 Oncogene Human genes 0.000 claims abstract description 24
229940124597 therapeutic agent Drugs 0.000 claims abstract description 15
239000003814 drug Substances 0.000 claims abstract description 13
210000000481 breast Anatomy 0.000 claims abstract description 8
238000000338 in vitro Methods 0.000 claims abstract description 7
230000027455 binding Effects 0.000 claims abstract description 5
230000002611 ovarian Effects 0.000 claims abstract description 3
210000002784 stomach Anatomy 0.000 claims abstract description 3
210000004027 cell Anatomy 0.000 claims description 409
230000003211 malignant effect Effects 0.000 claims description 60
108090000623 proteins and genes Proteins 0.000 claims description 53
102000004169 proteins and genes Human genes 0.000 claims description 53
101710081103 Cuticular glutathione peroxidase Proteins 0.000 claims description 30
230000005945 translocation Effects 0.000 claims description 26
239000003446 ligand Substances 0.000 claims description 23
230000014509 gene expression Effects 0.000 claims description 20
230000011712 cell development Effects 0.000 claims description 15
150000001875 compounds Chemical class 0.000 claims description 15
239000003795 chemical substances by application Substances 0.000 claims description 14
206010006187 Breast cancer Diseases 0.000 claims description 12
208000026310 Breast neoplasm Diseases 0.000 claims description 12
230000001413 cellular effect Effects 0.000 claims description 12
210000000805 cytoplasm Anatomy 0.000 claims description 12
230000000877 morphologic effect Effects 0.000 claims description 11
102000048238 Neuregulin-1 Human genes 0.000 claims description 10
108090000556 Neuregulin-1 Proteins 0.000 claims description 10
108010039491 Ricin Proteins 0.000 claims description 10
102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 8
108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 8
238000001574 biopsy Methods 0.000 claims description 8
210000001519 tissue Anatomy 0.000 claims description 8
230000009870 specific binding Effects 0.000 claims description 7
210000004408 hybridoma Anatomy 0.000 claims description 6
235000013336 milk Nutrition 0.000 claims description 5
239000008267 milk Substances 0.000 claims description 5
210000004080 milk Anatomy 0.000 claims description 5
239000012634 fragment Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000003053 toxin Substances 0.000 claims 2
231100000765 toxin Toxicity 0.000 claims 2
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
125000003473 lipid group Chemical group 0.000 claims 1
230000009257 reactivity Effects 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 52
150000002632 lipids Chemical class 0.000 description 40
239000012528 membrane Substances 0.000 description 34
230000024245 cell differentiation Effects 0.000 description 27
239000000523 sample Substances 0.000 description 25
239000005018 casein Substances 0.000 description 22
238000010186 staining Methods 0.000 description 22
230000004069 differentiation Effects 0.000 description 20
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 19
235000021240 caseins Nutrition 0.000 description 19
230000000694 effects Effects 0.000 description 17
230000003287 optical effect Effects 0.000 description 17
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 15
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 14
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 14
238000003556 assay Methods 0.000 description 12
238000001114 immunoprecipitation Methods 0.000 description 12
230000036210 malignancy Effects 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
230000006698 induction Effects 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
239000000427 antigen Substances 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
239000002609 medium Substances 0.000 description 9
238000002560 therapeutic procedure Methods 0.000 description 9
230000004614 tumor growth Effects 0.000 description 9
241000283707 Capra Species 0.000 description 8
101150029707 ERBB2 gene Proteins 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 8
230000001086 cytosolic effect Effects 0.000 description 8
230000012010 growth Effects 0.000 description 8
239000003656 tris buffered saline Substances 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
239000001963 growth medium Substances 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
238000011002 quantification Methods 0.000 description 7
230000001052 transient effect Effects 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
102000051957 human ERBB2 Human genes 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000002018 overexpression Effects 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
238000000211 autoradiogram Methods 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
230000008859 change Effects 0.000 description 5
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 5
239000000499 gel Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
210000004881 tumor cell Anatomy 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 4
NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
230000035578 autophosphorylation Effects 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
229940075911 depen Drugs 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000009826 distribution Methods 0.000 description 4
230000001747 exhibiting effect Effects 0.000 description 4
239000007850 fluorescent dye Substances 0.000 description 4
229960004279 formaldehyde Drugs 0.000 description 4
239000012737 fresh medium Substances 0.000 description 4
230000009036 growth inhibition Effects 0.000 description 4
230000002055 immunohistochemical effect Effects 0.000 description 4
238000012744 immunostaining Methods 0.000 description 4
229930182817 methionine Natural products 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
230000007306 turnover Effects 0.000 description 4
102000000905 Cadherin Human genes 0.000 description 3
108050007957 Cadherin Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000004624 confocal microscopy Methods 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
231100000599 cytotoxic agent Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000010828 elution Methods 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
235000020256 human milk Nutrition 0.000 description 3
210000004251 human milk Anatomy 0.000 description 3
238000010191 image analysis Methods 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
230000004807 localization Effects 0.000 description 3
239000013642 negative control Substances 0.000 description 3
238000011580 nude mouse model Methods 0.000 description 3
238000004393 prognosis Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
241000518994 Conta Species 0.000 description 2
101710112752 Cytotoxin Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
239000000470 constituent Substances 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
238000012303 cytoplasmic staining Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000002619 cytotoxin Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
238000000326 densiometry Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
108700020302 erbB-2 Genes Proteins 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000001744 histochemical effect Effects 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000000021 kinase assay Methods 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000035800 maturation Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000001000 micrograph Methods 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
102000027450 oncoproteins Human genes 0.000 description 2
108091008819 oncoproteins Proteins 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
238000003566 phosphorylation assay Methods 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
238000012809 post-inoculation Methods 0.000 description 2
239000011537 solubilization buffer Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
231100000588 tumorigenic Toxicity 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000001262 western blot Methods 0.000 description 2
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
241001514645 Agonis Species 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102100025805 Cadherin-1 Human genes 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
238000009649 Feulgen staining Methods 0.000 description 1
MFORDNZDKAVNSR-SRVKXCTJSA-N Gln-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O MFORDNZDKAVNSR-SRVKXCTJSA-N 0.000 description 1
YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
101000984015 Homo sapiens Cadherin-1 Proteins 0.000 description 1
101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
FQUUYTNBMIBOHS-IHRRRGAJSA-N Phe-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FQUUYTNBMIBOHS-IHRRRGAJSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
101100313929 Schizosaccharomyces pombe (strain 972 / ATCC 24843) tip1 gene Proteins 0.000 description 1
VMVNCJDKFOQOHM-GUBZILKMSA-N Ser-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N VMVNCJDKFOQOHM-GUBZILKMSA-N 0.000 description 1
YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
241000133063 Trixis Species 0.000 description 1
XQVRMLRMTAGSFJ-QXEWZRGKSA-N Val-Asp-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XQVRMLRMTAGSFJ-QXEWZRGKSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
238000007821 culture assay Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
230000007711 cytoplasmic localization Effects 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
-1 dichlorotriazinyl amino Chemical group 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000834 fixative Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
230000002621 immunoprecipitating effect Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
108010034529 leucyl-lysine Proteins 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical class [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
108010064235 lysylglycine Proteins 0.000 description 1
108010038320 lysylphenylalanine Proteins 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
230000017095 negative regulation of cell growth Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000034918 positive regulation of cell growth Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
FFISLTWEISOMFC-UHFFFAOYSA-N pyridin-2-yl propanedithioate Chemical compound CCC(=S)SC1=CC=CC=N1 FFISLTWEISOMFC-UHFFFAOYSA-N 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000013643 reference control Substances 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
238000003211 trypan blue cell staining Methods 0.000 description 1
108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA002145382A 1991-08-22 1992-08-21 Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement Abandoned CA2145382A1 (fr)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
IL99284		1991-08-22
IL99284A IL99284A0 (en)	1991-08-22	1991-08-22	Monoclonal antibodies to a growth factor receptor
US76704291A	1991-09-27	1991-09-27
US76704191A	1991-09-27	1991-09-27
US07/767,041		1991-09-27
US07/767,042		1991-09-27
CA002096417A CA2096417C (fr)	1991-08-22	1992-08-21	Methodes et compositions pour le traitement du cancer et pour predire les reactions a la therapie anticancereuse

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002096417A Division CA2096417C (fr)	1991-08-22	1992-08-21	Methodes et compositions pour le traitement du cancer et pour predire les reactions a la therapie anticancereuse

Publications (1)

Publication Number	Publication Date
CA2145382A1 true CA2145382A1 (fr)	1993-03-04

Family

ID=27427038

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002145382A Abandoned CA2145382A1 (fr)	1991-08-22	1992-08-21	Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement

Country Status (1)

Country	Link
CA (1)	CA2145382A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114269776A (zh) *	2019-04-18	2022-04-01	耶达研究及发展有限公司	源自活化car-t细胞的细胞外囊泡

1992
- 1992-08-21 CA CA002145382A patent/CA2145382A1/fr not_active Abandoned

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114269776A (zh) *	2019-04-18	2022-04-01	耶达研究及发展有限公司	源自活化car-t细胞的细胞外囊泡
CN114269776B (zh) *	2019-04-18	2025-01-07	耶达研究及发展有限公司	源自活化car-t细胞的细胞外囊泡

Legal Events

Date	Code	Title	Description
1995-03-23	EEER	Examination request
1997-08-21	FZDE	Dead

Publication	Publication Date	Title
EP0554441B1 (fr)	1999-01-27	Procedes et compositions de traitements de cancers et de pronostic de reactions auxdits traitements
US5288477A (en)	1994-02-22	Method for prognosticating response to cancer therapy
Bacus et al.	1992	Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells
CA1179952A (fr)	1984-12-27	Anticorps monoclonaux specifiques contre une glycoproteine humaine, la transferrine
AU679247B2 (en)	1997-06-26	Monoclonal antibodies against the alpha PDGF receptor and uses thereof
US10365283B2 (en)	2019-07-30	Activated HER3 as a marker for predicting therapeutic efficacy
JP4287147B2 (ja)	2009-07-01	小細胞肺癌（ｓｃｌｃ）の検出および治療のためのモノクローナル抗体および細胞表面抗原
NO319586B1 (no)	2005-08-29	Monoklonale antistoffer som gjenkjenner TIE-reseptor og deres anvendelse
Schmitt-Gräff et al.	1989	α-smooth muscle actin is expressed in a subset of bone marrow stromal cells in normal and pathological conditions
March et al.	2007	Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule
Zhang et al.	1999	Shared antigenic epitopes and pathobiological functions of anti-p185her2/neu monoclonal antibodies
WO2006015079A2 (fr)	2006-02-09	Agents de liaison de la famille erm et leur utilisation dans le diagnostic et le traitement d'etats proliferatifs
US20080267955A1 (en)	2008-10-30	Frizzled 9 as tumor marker
Friess et al.	1994	A subgroup of patients with chronic pancreatitis overexpress the c-erb B-2 protooncogene
KR20090059106A (ko)	2009-06-10	암 질환 변경 항체
Neville et al.	1982	Monoclonal antibodies and human tumor pathology
KR20090057970A (ko)	2009-06-08	Ｃｄ63의 세포 표면 발현을 증명하는 세포독성 중재
Kamma et al.	2001	Characterization of hnRNP A2 and B1 using monoclonal antibodies: intracellular distribution and metabolism through cell cycle
CA2145382A1 (fr)	1993-03-04	Methodes et compositions pour le traitement anticancereux et pour prevoir la reponse a ce traitement
US20040115741A1 (en)	2004-06-17	Method of quantifying antigen expression
Millar et al.	1988	A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro
IL103250A (en)	1999-03-12	Methods for pre-determining responses to cancer treatment
Orui et al.	1997	Proliferation and apoptosis of follicular lymphocytes: relationship to follicular dendritic cell‐associated clusters
US6074833A (en)	2000-06-13	Osteoblast and fibroblast antigen and antibodies recognizing it
US4962048A (en)	1990-10-09	Monoclonal antibodies to human pancreatic cancer